Overview

NBMI - Clinical Study on COPD

Status:
Completed

Trial end date:
2018-06-30

Target enrollment:

Participant gender:

Summary

A pilot study to explore safety of the treatment with the antioxidant and metal chelator NBMI in COPD patients. Investigational product: NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide Indication: Mild, moderate and severe COPD with bronchitis A randomised, two arm, double-blind, placebo-controlled, cross-over, once daily for 14 days pilot study in subjects with COPD with bronchitis.

Phase:

Phase 2

Details

Lead Sponsor:

EmeraMed

Treatments:

N,N'-Bis(2-mercaptoethyl)isophthalamide